Yarrow Bioscience director reports 175,639 stock options
Sven Ante Lundberg, a director of Yarrow Bioscience, Inc., filed an initial beneficial ownership report showing a stock option covering 175,639 shares of common stock at an exercise price of $6.19 per share, expiring on April 17, 2036.
Rhea-AI Filing Summary
Sven Ante Lundberg, a director of Yarrow Bioscience, Inc., filed an initial beneficial ownership report showing a stock option covering 175,639 shares of common stock at an exercise price of $6.19 per share, expiring on April 17, 2036.
The option was received in connection with a merger involving VYNE Therapeutics Inc. and Yarrow Bioscience, Inc. and was assumed on the same terms, with one quarter vesting on April 17, 2027 and the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Lundberg Sven Ante
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1, F2, F3 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 175,639 contracts (Direct)
Footnotes (3)
- F1. Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").
- F2. Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.
- F3. This option represents a right to purchase 175,639 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Underlying option shares: 175,639 shares
Exercise price: $6.19 per share
Option expiration: April 17, 2036
+3 more
6 metrics
Underlying option shares
175,639 shares
Stock option over Issuer Common Stock reported as of July 27, 2026
Exercise price
$6.19 per share
Exercise price for the stock option covering 175,639 shares
Option expiration
April 17, 2036
Expiration date of the reported stock option holding
Par value
$0.0001 per share
Par value of Issuer Common Stock underlying the option
Initial vesting date
April 17, 2027
One quarter of the option vests on this date, subject to continued service
Vesting duration for remainder
Three years
Remaining three quarters vest in equal monthly installments over three years after initial vesting
Key Terms
Effective Time, Merger, par value, vest
4 terms
Effective Time regulatory
"Effective as of July 27, 2026 (the "Effective Time")"
The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.
Merger financial
"a wholly owned subsidiary of VYNE Therapeutics Inc. merged with and into Yarrow"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
par value financial
"shares of common stock, par value $0.0001, of the Issuer"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
vest financial
"one quarter of which will vest on April 17, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did director Sven Ante Lundberg report in the Form 3 for VYNE?
Sven Ante Lundberg reported holding a stock option over 175,639 shares of Yarrow Bioscience common stock. The option has a $6.19 exercise price per share and expires on April 17, 2036, and is held as a direct beneficial interest.
How is the reported stock option for VYNE (Yarrow Bioscience) structured and vesting?
The option represents a right to purchase 175,639 shares of Issuer Common Stock. One quarter vests on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, conditioned on Lundberg’s continued service.
What merger led to the option reported for VYNE on this Form 3?
Effective July 27, 2026, a wholly owned subsidiary of VYNE Therapeutics Inc. merged with and into Yarrow Bioscience, Inc. Yarrow became a wholly owned subsidiary, and VYNE changed its name to Yarrow Bioscience, Inc.; Lundberg’s option was assumed in this merger.
What is the underlying security and par value in the VYNE director’s reported option?
The option is over shares of common stock of the issuer, referred to as Issuer Common Stock. These shares have a stated par value of $0.0001 per share, and the option maintains the same terms that applied before the merger.
Does the Form 3 for VYNE show any stock purchases or sales by Sven Ante Lundberg?
The report lists only a holding entry for a stock option and no buy or sell transactions. It reflects an existing option position that was converted and assumed in the merger, rather than newly executed market trades.
AI-generated analysis. How Rhea-AI works. Not financial advice.
